It is also exciting for treatment of other relapsed/refractory disease as this is a completely new pathway involving tumor-infiltrating macrophages and NK cells, which bypasses the PD-1/PD-L1 and CTLA4/CD80 pathways. This evidence concerns the gene CD274 and neoplasm.